米吉珠单抗治疗溃疡性结肠炎患者2期试验中持续治疗的疗效与安全性
本研究为I6T-MC-AMAC双盲试验的开放标签延长诱导部分,在14国75个中心进行。对12周诱导治疗无临床应答的中重度溃疡性结肠炎患者,接受600mg或1000mg米吉珠单抗静脉延长诱导12周,第24周临床应答者继续维持治疗。延长剂量可使至多50%的诱导无应答者产生临床应答,多数应答者维持至52周,未发现新安全性问题。
要点
- 对12周诱导无应答者,600mg组50.0%、1000mg组43.8%在延长12周后达到临床应答。
- 600mg组15.0%、1000mg组9.4%达到临床缓解,内镜改善分别为20.0%和15.6%。
- 第24周有临床应答并进入维持治疗者,第52周65.8%维持临床应答,26.3%临床缓解,34.2%内镜改善。
核心结论
- 延长12周给予米吉珠单抗600mg或1000mg可使至多50%对12周诱导剂量无临床应答的患者产生临床应答,多数延长剂量应答者维持临床应答至52周。
- 未发现新的安全性问题。
研究设计与样本
- 本研究为I6T-MC-AMAC双盲试验的延续,在14个国家75个中心进行。
- 中重度溃疡性结肠炎患者随机接受12周诱导治疗,剂量为米吉珠单抗50mg、200mg、600mg或安慰剂。
- 第12周无临床应答者进入开放标签延长诱导研究,接受600mg静脉米吉珠单抗(n=20)或方案修订后1000mg静脉米吉珠单抗(n=64),每4周一次,再治疗12周。
- 第24周临床应答者继续延长维持期,接受200mg皮下米吉珠单抗。
- 分析对象为诱导期接受米吉珠单抗或安慰剂的患者。
主要发现
- 对诱导米吉珠单抗无应答者中,接受12周延长600mg米吉珠单抗者50.0%达到临床应答,接受1000mg延长者43.8%达到临床应答。
- 600mg组15.0%和1000mg组9.4%分别达到临床缓解。
- 600mg组20.0%和1000mg组15.6%分别达到内镜改善。
- 对米吉珠单抗初始无应答且第24周有临床应答并继续维持治疗者,第52周65.8%维持临床应答,26.3%达到临床缓解,34.2%达到内镜改善。
- 未发现新的安全性问题。
关键数值与推荐
- 临床应答定义为Mayo子评分较基线下降≥2分且≥35%,同时直肠出血子评分下降≥1分或直肠出血子评分为0或1。
- 临床缓解定义为直肠出血Mayo子评分为0,且排便频率子评分为0或1且较基线下降1分。
- 内镜缓解定义为Mayo内镜子评分为0。
- 内镜改善定义为内镜子评分为0或1。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Mirikizumab is an antibody against the p19 subunit of interleukin 23 that has demonstrated clinical efficacy and was well tolerated following 12 weeks of induction treatment in a phase 2 trial of patients with moderate to severe ulcerative colitis. We present results of the open-label extended induction period in patients who did not initially respond to treatment with mirikizumab. METHODS: This study was a continuation of I6T-MC-AMAC, a double-blind trial, performed at 75 sites in 14 countries, in which patients with moderate to severe ulcerative colitis were randomly assigned to 12 weeks induction therapy with 50 mg, 200 mg, or 600 mg mirikizumab or placebo. Patients without a clinical response (a 9-point decrease in Mayo subscore of ≥2 points and ≥35% from baseline and either a decrease of rectal bleeding subscore of ≥1 or a rectal bleeding subscore of 0 or 1) at week 12 were offered the opportunity to participate in an open-label, extended induction study for another 12 weeks, in which they received either 600 mg intravenous mirikizumab (n = 20) or, following a protocol amendment, 1000 mg intravenous mirikizumab (n = 64) every 4 weeks. At week 24, patients with a clinical response continued the extension maintenance period and received 200 mg subcutaneous mirikizumab. Endpoints included clinical remission (Mayo subscores of 0 for rectal bleeding, 0 or 1 with a 1-point decrease from baseline), clinical response, endoscopic remission (Mayo endoscopic subscore of 0), or endoscopic improvement (endoscopic subscore of 0 or 1), at study weeks 24 and 52. Data were analysed for patients who received mirikizumab or placebo during the induction phase of the study. RESULTS: Among participants who did not respond to induction mirikizumab, 50.0% of those who received the 12-week extension of 600 mg mirikizumab and 43.8% who received the extension of 1000 mg mirikizumab achieved a clinical response; 15.0% and 9.4% achieved clinical remission, respectively. Endoscopic improvement was achieved by 20.0% of subjects in the 600 mg mirikizumab group and 15.6% subjects in the 1000 mg mirikizumab group. Among initial nonresponders to mirikizumab who had clinical response at study week 24 and continued into maintenance therapy, 65.8% maintained the clinical response, 26.3% achieved clinical remission, and 34.2% had endoscopic improvement at week 52. No new safety concerns were identified. CONCLUSIONS: Extended doses of mirikizumab (600 mg and 1000 mg) for an additional 12 weeks produce a clinical response in up to 50% of patients who did not have a clinical response to 12 weeks of induction doses (50 mg, 200 mg, or 600 mg). Most of the responders to the extended doses maintained clinical response for up to 52 weeks. Clinicaltrials.gov no: NCT02589665.
引用
- Sandborn WJ, Ferrante M, Bhandari BR, et al. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020. PMID: 32950748. doi:10.1016/j.cgh.2020.09.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。